Open AccessInsights into the potential role of alpha1‐antitrypsin in COVID‐19 patients: Mechanisms, current update, and future perspectives
Author(s) -
Marzouk Saber,
Attia Noha,
Mashal Mohamed
Publication year - 2021
Publication title -
the clinical respiratory journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.789
H-Index - 33
eISSN - 1752-699X
pISSN - 1752-6981
DOI - 10.1111/crj.13406
Subject(s) - covid-19 , medicine , genetic enhancement , clinical trial , intensive care medicine , bioinformatics , gene , virology , pathology , genetics , disease , biology , outbreak , infectious disease (medical specialty)
In this work, we provide an up‐to‐date summary of the available molecular‐ and cell‐related mechanisms by which alpha1‐antitrypsin (AAT) protein could be of benefit in treating COVID‐19 patients. As well, we demonstrate the current status in terms of the ongoing clinical trials using AAT in COVID‐19 patients. Finally, we touch on the potential role gene therapy and stem cell‐based gene therapy could have in such emerging and serious condition caused by the SARS‐CoV‐2 virus.